Trump Admin Plans Pilot Medicare Coverage for Ozempic, Wegovy in Obesity Fight

The Trump administration plans a five-year pilot to optionally cover GLP-1 weight-loss drugs like Ozempic and Wegovy under Medicare and Medicaid for obesity treatment, starting in 2026-2027. This reversal from prior restrictions aims to assess costs and outcomes amid surging demand. Success could transform public health approaches to obesity.